RxDoctor Payments Data

Julien Norton, MD

Otolaryngology · Charleston, SCNPI 1508124348

Payments from drug & device makers

$2,641in general payments, 2019–2025

Across 82 payments — averaging $32.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$988
  • Regeneron Healthcare Solutions, Inc.$436
  • Sanofi$381
  • GSK$276
  • Optinose US, Inc.$233
  • Sanofi-aventis U.S. LLC$95
  • plus $231 from 8 others

What the payments were for

  • Food & beverage$2,54696%
  • Education$954%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,641 in reported general payments places this provider in the 55th percentile of 180 otolaryngology providers in South Carolina.

See all otolaryngology providers in South Carolina

Medicare billing

Part B allowed, 2024
$420,448
Medicare patients
1,444
Services billed
10,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Azelastine Hcl317$10,514
Ipratropium Bromide216$6,109
Epinephrine29$5,512
Breo ElliptaFluticasone/Vilanterol12$4,483
Fluticasone Propionate283$3,851
Ofloxacin43$1,542
Famotidine227$1,506
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth11$1,313
Cefdinir52$1,005
Montelukast Sodium70$894
Omeprazole113$841
Clarithromycin32$570
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip47$494
Prednisone162$347
Mupirocin38$302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKBreo Ellipta$276$4,48312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 180 otolaryngology providers in South Carolina.

Other otolaryngology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →